The Serum IL-6 Profile and Treg/Th17 Peripheral Cell Populations in Patients with Type 1 Diabetes

Ryba-Stanisławowska, Monika; Skrzypkowska, Maria; Myśliwska, Jolanta; Myśliwiec, Małgorzata

doi:10.1155/2013/205284

Cited by 43 publications

(31 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reported high production of Th1 cytokines and low production of Th2 cytokines in T1D [311], confirming results from animal studies [305], while others detected low production of Th1 cytokines in peripheral blood [312]. Furthermore, up-regulation of the Th17 cell associated cytokine IL-17 has been reported in peripheral blood of T1D patients [313][314][315][316]. …”

Section: Development Of T1d/(molecular) Pathogenesissupporting

confidence: 56%

Studies of Mucosal Immune Regulation in Celiac Disease and Type 1 Diabetes

Lahdenperä¹

2014

View full text Add to dashboard Cite

Section: Development Of T1d/(molecular) Pathogenesissupporting

confidence: 56%

Studies of Mucosal Immune Regulation in Celiac Disease and Type 1 Diabetes

Lahdenperä¹

2014

View full text Add to dashboard Cite

“…Our previous studies suggested that inflammation associated with long-lasting T1DM was responsible for such an effect on Tregs. These cells were characterized by decreased expression of FoxP3 and CD62L under proinflammatory conditions, and this effect could be reverted using anti-inflammatory agents [16–19]. It was intriguing that, in the current study, gradual increase in the level of proinflammatory cytokines was seen early, starting from the clinical onset of T1DM.…”

Section: Discussionmentioning

confidence: 76%

Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Recent studies suggest that immunotherapy using T regulatory cells (Tregs) prolongs remission in type 1 diabetes (T1DM). Here, we report factors that possibly affect the efficacy of this treatment. Methods:The metabolic and immune background of 12 children with recently diagnosed T1DM, as well as that of untreated subjects, during a 2-year follow-up is presented. Patients were treated with up to 30 × 10 6 /kg b.w. of autologous expanded CD3 Results:The disease progressed and all patients were insulin-dependent 2 years after inclusion. The β-cell function measured by c-peptide levels and the use of insulin were the best preserved in patients treated with two doses of Tregs (3/6 in remission), less so after one dose (1/6 in remission) and the worst in untreated controls (no remissions). Increased levels of Tregs could be seen in peripheral blood after their adoptive transfer together with the shift from naïve CD62L + CD45RA + to memory CD62L + CD45RA − Tregs. Increasing serum levels of proinflammatory cytokines were found: IL6 increased in all subjects, while IL1 and TNFα increased only in untreated group. Therapeutic Tregs were dependent on IL2, and their survival could be improved by other lymphocytes. Conclusions:The disease progression was associated with changing proportions of naïve and memory Tregs and slowly increasing proinflammatory activity, which was only partially controlled by the administered Tregs. The therapeutic cells were highly dependent on IL2. We conclude that the therapy should be administered at the earliest to protect the highest possible mass of islets and also to utilize the preserved content of Tregs in the earlier phases of T1DM. Trial registration http://www.controlled-trials.com/ISRCTN06128462; registered retrospectively

show abstract

“…In fact, besides an increase of circulating Th17 cells, a reduction of Treg cells in the peripheral blood of patients with T1D has also been reported [46].…”

Section: Discussionmentioning

confidence: 94%